Novartis Announces Positive Results For Cardiovascular Drug
Zacks Investment Research | Jun 21, 2017 09:47PM ET
Novartis AG (NYSE:NVS) announced positive top-line results from the global phase III study, CANTOS. The study evaluated the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination with standard of care in patients with a prior heart attack and inflammatory atherosclerosis.
CANTOS is a randomized, double-blind, placebo-controlled, event-driven phase III study. It is designed to evaluate the efficacy, safety and tolerability of quarterly subcutaneous injections of canakinumab in combination with standard of care in the prevention of recurrent cardiovascular (CV) events. The study enrolled patients with a prior myocardial infarction (MI) and with a high-sensitivity C-reactive protein (hsCRP).
The study met the primary endpoint as the candidate demonstrated canakinumab when used in combination with standard of care reduced the risk of major adverse cardiovascular events (MACE). Novartis will present the full data later in 2017.
Approximately 580,000 people in the EU and 750,000 people in the U.S. are affected by heart attacks every year. Heart patients remain susceptible to a second attack and even death. 25% of heart attack survivors are estimated to experience another cardiovascular event within five years. Among four in 10 patients, the risk is directly related to increased inflammation associated with atherosclerosis thereby highlighting the great need for treatments like canakinumab.
The successful development and commercialization of canakinumab will significantly boost Novartis’ cardiovascular portfolio. The company currently has Entresto in its portfolio which has been given a Class I recommendation in the U.S. and EU clinical guidelines for the treatment of heart failure with reduced ejection fraction (HFrEF).
We remind investors that canakinumab was first approved in 2009 for cryopyrin-associated periodic syndromes as Ilaris. In 2016, the FDA approved the label expansion of the drug to treat three rare and distinct types of periodic fever syndromes – tumor necrosis factor-receptor associated periodic syndrome, hyperimmunoglobulin D syndrome / mevalonate kinase deficiency and familial Mediterranean fever.
Novartis has outperformed the Zacks classified industry in the last six months. The stock has rallied 15.0% compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.